A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology
Globe Newswire (Thu, 14-May 9:15 AM ET)
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
Globe Newswire (Wed, 29-Apr 8:44 AM ET)
Globe Newswire (Thu, 23-Apr 8:35 AM ET)
Radiopharm Theranostics Reports Business Update
Globe Newswire (Thu, 23-Apr 7:00 AM ET)
Globe Newswire (Mon, 20-Apr 7:00 AM ET)
Globe Newswire (Thu, 16-Apr 7:00 AM ET)
Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
Globe Newswire (Wed, 8-Apr 7:00 AM ET)
Globe Newswire (Tue, 7-Apr 7:00 AM ET)
Globe Newswire (Fri, 27-Mar 7:00 AM ET)
Globe Newswire (Tue, 24-Mar 7:00 AM ET)
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
Radiopharm Theranostics Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol RADX.
As of June 4, 2026, RADX stock price climbed to $4.63 with 25,854 million shares trading.
RADX has a beta of -0.28, meaning it tends to be less sensitive to market movements. RADX has a correlation of 0.00 to the broad based SPY ETF.
RADX has a market cap of $36.02 million. This is considered a Sub-Micro Cap stock.
RADX has underperformed the market in the last year with a price return of -5.5% while the SPY ETF gained +28.2%. RADX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -4.8% and +1.1%, respectively, while the SPY returned +11.5% and +2.1%, respectively.
RADX support price is $4.30 and resistance is $4.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RADX shares will trade within this expected range on the day.